⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17393064 | 0.97 | LMNA (0.65) | — | |
| SCHEMBL259497 | 0.86 | PIK3CD (0.62) | — | |
| Hydrochloric Acid SCHEMBL4659475 | 0.83 | PIK3CD (0.59) | — | |
| Mechlorethamine SCHEMBL3861 | 0.80 | — | — | |
| Mechlorethamine SCHEMBL11905424 | 0.80 | MAPT (1.00) | — | |
| SCHEMBL12455820 | 0.78 | PIK3CD (0.54) | — | |
| Mechlorethamine SCHEMBL5330778 | 0.76 | LMNA (1.00) | — | |
| Mechlorethamine SCHEMBL3855 | 0.76 | — | — | |
| Mechlorethamine SCHEMBL2554459 | 0.76 | — | — | |
| Mechlorethamine SCHEMBL10618376 | 0.76 | LMNA (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-10-12 | — | — | US | disclosed |
| EP-3192511-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-9499553-B2 | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20160002251-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-07 | — | — | US | disclosed |
| US-6960590-B2 | Orally active salts with tyrosine kinase activity | MERCK & CO. INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1328519-B1 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1328519-A4 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040002501-A1 | Orally active salts with tyrosine kinase activity | FRALEY MARK E (US) | 2004-01-01 | — | — | US | disclosed |
| US-6656942-B2 | For therapy of diseases such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals | MERCK & CO., INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1328519-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | Merck & Co., Inc. (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | MERCK & CO., INC. | 2002-06-13 | — | — | US | disclosed |
| WO-2002032861-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO., INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| US-4520131-A | WATER-SOLUBLE VASODIALATORS | USV PHARMACEUTICAL (US) | 1985-05-28 | — | — | US | disclosed |